Ten-year outcome of Eculizumab in kidney transplant recipients with atypical hemolytic uremic syndrome– a single center experience

Ten-year outcome of Eculizumab in kidney transplant recipients with atypical hemolytic uremic syndrome– a single center experience

Abstract Background Atypical hemolytic uremic syndrome (aHUS) can result in severe kidney dysfunction, secondary to thrombotic microangiopathy. Eculizumab has been used to treat this disorder, and has resulted in favourable outcomes in both, native and transplanted kidneys. There is limited long ter...

Full description

Bibliographic Details
Main Authors: Sam Kant, Anshul Bhalla, Sami Alasfar, Nada Alachkar
Format: Article
Language:English
Published: BMC 2020-05-01
Series:BMC Nephrology
Subjects:
Eculizumab
Atypical hemolytic uremic syndrome
Kidney transplant
Online Access:http://link.springer.com/article/10.1186/s12882-020-01847-0

Internet

http://link.springer.com/article/10.1186/s12882-020-01847-0

Similar Items